New NCCN guidelines recognize the utility of MammaPrint for guiding anthracycline therapy selection in HR+/HER2- early-stage ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
The Viz Oncology Suite is a clinical decision support system that integrates seamlessly with the electronic health record to ...
PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care. Panelists discuss how payer coverage often ...
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...
Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
The National Comprehensive Cancer Network (NCCN) started the roll-out of a new digital format designed to streamline access and use of the organization's 88 clinical guidelines. The digital makeover, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback